Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.
{{Infobox drug | image = Ozanimod.svg | image_class = skin-invert-image | width = 285 | alt = | image2 = Ozanimod ball-and-stick model.png | image_class2 = bg-transparent | width2 = | alt2 = | caption =
| pronounce = | tradename = Zeposia | Drugs.com = | MedlinePlus = a620029 | licence_CA = | licence_EU = yes | DailyMedID = Ozanimod | licence_US = | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L04 | ATC_suffix = AE02 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).